Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | MAN2A1 | Q16706 | 1/20 | 0.38 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.38 |
| ▸ | TRPM5 | Q9NZQ8 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13966475 | 1.00 | MGAM (0.50) | MGAMCHRNA7SMN1; SMN2LMNAGAA | |
| SCHEMBL830730 | 1.00 | MGAM (0.50) | MGAMCHRNA7SMN1; SMN2LMNAGAA | |
| SCHEMBL835907 | 1.00 | MGAM (0.50) | MGAMCHRNA7SMN1; SMN2LMNAGAA | |
| SCHEMBL830731 | 1.00 | MGAM (0.50) | MGAMCHRNA7SMN1; SMN2LMNAGAA | |
| SCHEMBL13538449 | 0.83 | MGAM (0.73) | MGAMGAAGBA1MAN2A1MAN1B1 | |
| SCHEMBL17622803 | 0.83 | MGAM (0.73) | MGAMGAAGBA1MAN2A1MAN1B1 | |
| SCHEMBL19258270 | 0.83 | MGAM (0.73) | MGAMGAAGBA1MAN2A1MAN1B1 | |
| SCHEMBL9789772 | 0.81 | MGAM (0.71) | MGAMGAAGBA1MAN2A1MAN1B1 | |
| SCHEMBL29299975 | 0.81 | MEN1 (0.57) | MGAMCHRNA7SMN1; SMN2LMNAGAA | |
| SCHEMBL29299973 | 0.81 | MEN1 (0.57) | MGAMCHRNA7SMN1; SMN2LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143375-B2 | Aziridine aldehydes, aziridine-conjugated amino derivatives, aziridine-conjugated biomolecules and processes for their preparation | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2012-03-27 | — | — | US | disclosed |
| US-20100317832-A1 | AZIRIDINE ALDEHYDES, AZIRIDINE-CONJUGATED AMINO DERIVATIVES, AZIRIDINE-CONJUGATED BIOMOLECULES AND PROCESSES FOR THEIR PREPARATION | ZEALAND PHARMA A/S (DK) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317832-A1 | AZIRIDINE ALDEHYDES, AZIRIDINE-CONJUGATED AMINO DERIVATIVES, AZIRIDINE-CONJUGATED BIOMOLECULES AND PROCESSES FOR THEIR PREPARATION | QDPR, VIP, AAAS | MGAM 3893/4885CHRNA7 3151/4885SMN1; SMN2 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.